Please login to the form below
The New England Journal of Medicine
This page shows the latest The New England Journal of Medicine news and features for those working in and with pharma, biotech and healthcare.
Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease
The results from the BOREAS trial, which met the primary and all secondary endpoints, were simultaneously published in the New England Journal of Medicine. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of the
Latest news
-
Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
More than 47, 000 new cases of prostate cancer are diagnosed every year in England. ... The results, published in the New England Journal of Medicine, also showed a 32.5% reduction in the risk of death in the Nubeqa group compared to the placebo.
-
Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
Almirall’s lebrikizumab was associated with significant improvements in moderate-to-severe atopic dermatitis symptoms, according to phase 3 results recently published in the New England Journal of Medicine (NEJM) and ... Jonathan Silverberg, professor
-
Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
journey.”. The company said results from the trial will be presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, as well as published in the New ... England Journal of Medicine.
-
Esperion’s heart drug shown to reduce risk of major adverse cardiovascular events
The results, which have also been published in the New England Journal of Medicine, showed the drug reduced the risk of hard MACE-4 and MACE-3 by 13% and 15%, ... Cardiovascular diseases are the leading cause of death globally, according to the World
-
Results for GSK’s RSV vaccine candidate published in New England Journal of Medicine
to results recently published in the New England Journal of Medicine. ... coordinator of the vaccine clinical trials unit at the Instituto de Investigación Sanitaria de Santiago in Spain.
More from news
Approximately 2 fully matching, plus 196 partially matching documents found.
Latest Intelligence
-
Creating truly effective communications – the impact of high speed, high octane messaging
In medcomms, for example, there can be an over-reliance on publishing in top-tier journals like The New England Journal of Medicine, which might reach just a small proportion of ... There is also a core need, Rogers observed, to recognise that there is a
-
The search for effective drug treatments for COVID-19
This data was peer-reviewed and published in the New England Journal of Medicine. ... The data was peer-reviewed and published in the Journal of the American Medical Association (JAMA).
-
Developing a COVID-19 vaccine
In an article published by The New England Journal of Medicine, Nicole Lurie, Melanie Saville, Richard Hatchett and Jane Halton from the CEPI urged caution: ‘Vaccine development is a lengthy, expensive ... That includes possible changes to ongoing
-
As COVID-19 takes over the world, biopharma fights back
As confirmed cases of the novel coronavirus worldwide surge over 939, 436 (as of 2 April), all eyes are firmly set on the pharmaceutical and life sciences industries for the development ... Although the data, published in The New England Journal of
-
Is anybody listening?
Evidence-based listening. The evidence-base is growing. A study published in the Journal of Medical Internet Research shows how ‘social ties’ formed in online spaces provide the basis for both ... A recent study in the New England Journal of Medicine
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office
OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, announced a new team of experts will lead its HEOR &Market Access Scientific Office. ... He was also one of the first researchers to perform a
-
Improving healthcare for rare disease patients
The pilot study, published in the New England Journal of Medicine in 2021,. ... Accessed March 1, 2022. NHS England. NHS England announces new Innovative Medicines Fund to fast-track promising new drugs.
-
Barber shops provide a short cut to BP reduction
The basics of preventive medicine are cut and dried: don't smoke, eat less, drink less, exercise more, and reduce your risk factors for life-limiting illnesses like cardiovascular disease, diabetes ... The study, published in the New England Journal of
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
The Creative Engagement Group
We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
